Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / GuangZhou Cellgenes Biotechnology Co., Ltd.

Clinicaltrial registered27 Oct 2026

GuangZhou Cellgenes Biotechnology Co., Ltd.

27 Oct 2026: Trial registered · Safety and Efficacy of CG-BM1 in Ischemic Stroke. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
27 Oct 2026
Title
Safety and Efficacy of CG-BM1 in Ischemic Stroke
Conditions
Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07896941
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at GuangZhou Cellgenes Biotechnology Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for GuangZhou Cellgenes Biotechnology Co., Ltd. in our registers.

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.